Conste que la Fase III está en curso e incluso ha terminado ya el Reclutamiento de Pacientes .
Por todos sabido que la posible salida al Mercado de Zepsyre dependerá de la Supervivencia Global que se obtenga en la FIII :
03 agosto 2018
Pharmamar Marine Drugs . Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A .
Published : 31 July 2018.
Abstract
Jomthonic acids (JAs) are a group of natural products (NPs) with adipogenic activity. Structurally, JAs are formed by a modified β-methylphenylalanine residue, whose biosynthesis involves a methyltransferase that in Streptomyces hygroscopicus has been identified as MppJ. Up to date, three JA members (A–C) and a few other natural products containing β-methylphenylalanine have been discovered from soil-derived microorganisms. Herein, we report the identification of a gene (jomM) coding for a putative methyltransferase highly identical to MppJ in the chromosome of the marine actinobacteria Streptomyces caniferus GUA-06-05-006A. In its 5’ region, jomM clusters with two polyketide synthases (PKS) (jomP1, jomP2), a nonribosomal peptide synthetase (NRPS) (jomN) and a thioesterase gene (jomT), possibly conforming a single transcriptional unit. Insertion of a strong constitutive promoter upstream of jomP1 led to the detection of JA A, along with at least two novel JA family members (D and E). Independent inactivation of jomP1, jomN and jomM abolished production of JA A, JA D and JA E, indicating the involvement of these genes in JA biosynthesis. Heterologous expression of the JA biosynthesis cluster in Streptomyces coelicolor M1152 and in Streptomyces albus J1074 led to the production of JA A, B, C and F. We propose a pathway for JAs biosynthesis based on the findings here described. ...
Jomthonic acids (JAs) are a group of natural products (NPs) with adipogenic activity. Structurally, JAs are formed by a modified β-methylphenylalanine residue, whose biosynthesis involves a methyltransferase that in Streptomyces hygroscopicus has been identified as MppJ. Up to date, three JA members (A–C) and a few other natural products containing β-methylphenylalanine have been discovered from soil-derived microorganisms. Herein, we report the identification of a gene (jomM) coding for a putative methyltransferase highly identical to MppJ in the chromosome of the marine actinobacteria Streptomyces caniferus GUA-06-05-006A. In its 5’ region, jomM clusters with two polyketide synthases (PKS) (jomP1, jomP2), a nonribosomal peptide synthetase (NRPS) (jomN) and a thioesterase gene (jomT), possibly conforming a single transcriptional unit. Insertion of a strong constitutive promoter upstream of jomP1 led to the detection of JA A, along with at least two novel JA family members (D and E). Independent inactivation of jomP1, jomN and jomM abolished production of JA A, JA D and JA E, indicating the involvement of these genes in JA biosynthesis. Heterologous expression of the JA biosynthesis cluster in Streptomyces coelicolor M1152 and in Streptomyces albus J1074 led to the production of JA A, B, C and F. We propose a pathway for JAs biosynthesis based on the findings here described. ...
Zepsyre . FDA ha concedido a lurbinectedina, molécula de PharmaMar, la designación de medicamento huérfano .
Pharma Mar said its drug Lurbinectedin had been granted orphan status by the Food and Drug Administration (FDA) of the U.S. for the treatment of small cell lung cancer .
Medicamentos Huérfanos :
Fármacos que no son desarrollados por la industria farmacéutica por razones económicas pero que responden a necesidades de salud públicas .
Luis Mora :
... Es una gran satisfacción recibir esta designación de medicamento huérfano, ya que
subraya la gran necesidad de tratamientos innovadores y efectivos para este tipo de
cáncer y reconoce los beneficios potenciales que lurbinectedina puede proporcionar a los pacientes con cáncer de pulmón microcítico", ha dicho Luis Mora, Director General de la Unidad de Negocio de Oncología de PharmaMar.
"Recibir la designación de medicamento huérfano para el tratamiento del cáncer de pulmón de células Pequeñas es un hito regulatorio importante en el desarrollo de lurbinectedin", ha añadido.
Fármacos que no son desarrollados por la industria farmacéutica por razones económicas pero que responden a necesidades de salud públicas .
Luis Mora :
... Es una gran satisfacción recibir esta designación de medicamento huérfano, ya que
subraya la gran necesidad de tratamientos innovadores y efectivos para este tipo de
cáncer y reconoce los beneficios potenciales que lurbinectedina puede proporcionar a los pacientes con cáncer de pulmón microcítico", ha dicho Luis Mora, Director General de la Unidad de Negocio de Oncología de PharmaMar.
"Recibir la designación de medicamento huérfano para el tratamiento del cáncer de pulmón de células Pequeñas es un hito regulatorio importante en el desarrollo de lurbinectedin", ha añadido.
